Which statement is true regarding Entamoeba histolytica?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The true statement regarding Entamoeba histolytica is that Diloxanide Furoate is an effective luminal agent. This is based on the understanding that Entamoeba histolytica is a protozoan parasite that causes amebiasis, an intestinal infection characterized by dysentery and potential extraintestinal complications.

  • Entamoeba histolytica possesses cytolytic enzymes that allow it to break down host tissues and invade beyond the intestinal lumen into the colonic wall, causing ulcerations and, in some cases, spreading to other organs like the liver where it can form abscesses.
  • Infection typically occurs through ingestion of cysts in contaminated food or water, with symptoms ranging from mild diarrhea to severe dysentery with bloody stools.
  • Treatment for invasive amebiasis usually involves metronidazole (500-750 mg three times daily for 7-10 days) followed by a luminal agent like paromomycin (25-35 mg/kg/day in three divided doses for 7 days) or Diloxanide Furoate to eliminate cyst passage and prevent transmission, as supported by 1.
  • The use of Diloxanide Furoate as a luminal agent is specifically highlighted for its effectiveness in treating the luminal phase of the infection, making option A the correct statement regarding Entamoeba histolytica. Key points to consider in the management of Entamoeba histolytica infection include:
  • Accurate diagnosis through stool examination or serological tests to distinguish it from non-pathogenic amoebas.
  • Prompt treatment with metronidazole for invasive disease, followed by a luminal agent.
  • Prevention of transmission through improved sanitation and hygiene practices. Given the potential for severe complications, including extraintestinal disease, it is crucial to prioritize effective treatment and prevention strategies, as outlined in guidelines such as those provided by 1.

From the Research

Entamoeba histolytica Statements

  • The following statements are given regarding Entamoeba histolytica:
    • A. Diloxanide Furoate is an effective luminal agent
    • B. It is a common cause of traveler’s diarrhea
    • C. It may cause pyogenic liver abscess
    • D. It usually cause abscess in the left lobe of the liver
    • E. Metronidazole is ineffective in treating invasive disease

Analysis of Statements

  • Statement A: Diloxanide Furoate is an effective luminal agent. This statement is supported by studies 2, 3, 4, 5, which show that diloxanide furoate is used for treating asymptomatic or mildly symptomatic persons who are passing cysts of Entamoeba histolytica and is effective in treating luminal infections.
  • Statement B: It is a common cause of traveler’s diarrhea. There is no evidence in the provided studies to support this statement.
  • Statement C: It may cause pyogenic liver abscess. While Entamoeba histolytica can cause liver abscess, the provided studies 3, 4 do not specify that it is pyogenic.
  • Statement D: It usually cause abscess in the left lobe of the liver. The provided studies do not specify the location of the liver abscess.
  • Statement E: Metronidazole is ineffective in treating invasive disease. This statement is not supported by the studies 3, 4, 5, which show that metronidazole is effective in treating invasive amebiasis, including amebic liver abscess.

Correct Statement

  • Based on the analysis, statement A is the correct statement, as diloxanide furoate is an effective luminal agent for treating Entamoeba histolytica infections, as supported by studies 2, 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

Therapy of entamebiasis.

Journal of chemotherapy (Florence, Italy), 1989

Research

[Therapy for malaria and amoebiasis].

Immunitat und Infektion, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.